From $680 Million to $3.8 Billion: The Anatomy of a Strategic Premium

Procter & Gamble agreed this week to acquire Thorne, a premium supplement maker, for $3.8 billion in cash from private equity firm L Catterton. The seller took the company private less than three years ago in a deal valued at roughly $680 million. The distance between those two prices is not a rounding error or a market anomaly; it is a clean illustration of how the value of a business depends on who is buying it, and why.

Three Prices, One Company

Thorne has now been priced three times in five years, and each price tells you something different. The company went public in late 2021 at a valuation of about $525 million. In 2023, L Catterton, the consumer-focused private equity firm backed by LVMH, took it private at roughly $680 million. This week, P&G agreed to pay $3.8 billion, with the deal expected to close in the fourth quarter of 2026.

The headline arithmetic is striking on its own: the strategic sale price is more than five times the take-private price. But the more useful observation for a business owner is that none of these three prices was wrong. Each reflected what a specific type of buyer, at a specific moment, could justify paying. Public market investors in 2021 priced a small-cap consumer stock in a crowded category. A private equity sponsor in 2023 priced a standalone business it would need to grow and eventually resell, and it bought at a moment when valuations for smaller public companies were depressed. A strategic acquirer in 2026 priced what Thorne is worth inside P&G, which is a different question entirely.

Reports put Thorne on track for roughly $650 million in sales this year, which means P&G is paying close to six times revenue. Multiples like that do not come from spreadsheets alone. They come from what the buyer believes it can do with the asset that no one else can.

What Changed Inside the Business

Part of the answer is performance itself. Thorne's revenue surpassed $500 million in 2025 and continued growing into 2026. L Catterton did what consumer-focused sponsors are supposed to do: it scaled distribution, sharpened the brand's premium positioning, and kept the company anchored in the practitioner and performance channels that gave it credibility with consumers willing to pay more for tested, higher-quality products.

That operational story matters, but it does not fully explain the price. A business that grows revenue meaningfully might justify a proportional increase in value, yet Thorne's price grew far faster than its sales did. The remainder of the gap comes from two forces that owners consistently underestimate: buyer-specific value and competitive tension.

Why a Strategic Buyer Pays What a Sponsor Will Not

A financial buyer, such as a private equity fund, prices a business largely on its standalone cash flows. The fund has to underwrite a return based on what the company can earn by itself, plus whatever improvements the fund can drive, minus the cost of eventually finding the next buyer. Discipline about entry price is structural: overpaying is the one mistake a sponsor cannot manage its way out of.

A strategic buyer runs different math. P&G already owns a portfolio of wellness brands, including Metamucil, Align, and New Chapter, and it operates one of the deepest retail distribution networks in consumer goods. When P&G models Thorne, it is not pricing the company's standalone future. It is pricing Thorne's products flowing through P&G's shelf space, retail relationships, and international infrastructure, a set of advantages usually described as synergies: the additional revenue and cost savings that exist only when two businesses combine.

There is also the build-versus-buy calculation. P&G could develop a premium supplement brand internally, but establishing the clinical reputation and practitioner trust that Thorne spent decades accumulating would take years, with no guarantee of success, in a category where consumer demand is compounding now. Buying the finished asset at a full price can still be cheaper than building a copy slowly. Scarcity amplifies this: there are very few supplement businesses with Thorne's combination of scale, growth, and premium credibility, and scarce assets in strategic categories get priced by what the acquirer stands to lose by not owning them.

The Auction Effect

Competitive tension did real work here as well. Reports surfaced in June that Haleon, the consumer health company spun out of GSK, had bid for Thorne. Whether or not that process ever became a formal auction, the presence of a credible rival changes the arithmetic for everyone. A buyer negotiating against no one anchors to its own model. A buyer negotiating against a competitor anchors to the cost of losing the asset to that competitor, which in strategic categories is often the larger number.

This is a process lesson as much as a market lesson. Sellers rarely receive buyer-specific value as a gift; they extract it because more than one buyer was forced to price the asset at the same time. For owners, the implication is that how you run a sale process can matter nearly as much as what you built.

What This Resets for Other Owners

Transactions like this one recalibrate expectations across an entire category. Owners of scaled, premium consumer health brands now have a marker for what a motivated strategic will pay, and buyers know that sellers have seen it. That tends to lift the clearing price for truly comparable assets, meaning businesses with real brand equity, category leadership, and durable growth.

The caution is in the word comparable. Strategic premiums concentrate at the top of a category. The same market that pays six times revenue for a category leader will pay ordinary prices, or decline to bid at all, for undifferentiated businesses in the same industry. Owners who read headline multiples as a general repricing of their industry routinely walk into sale processes with expectations no buyer will meet.